{"id":68343,"date":"2026-06-16T22:50:21","date_gmt":"2026-06-16T14:50:21","guid":{"rendered":"https:\/\/flcube.com\/?p=68343"},"modified":"2026-06-16T22:50:22","modified_gmt":"2026-06-16T14:50:22","slug":"zelgen-biopharmaceuticals-secures-nmpa-approval-for-zepuping-in-severe-alopecia-areata-first-immuno-inflammatory-indication-for-pan-jak-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68343","title":{"rendered":"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has granted approval for its independently developed <strong>Zepuping (gecacitinib)<\/strong> for the treatment of <strong>severe alopecia areata in adults<\/strong>. This marks the <strong>second approved indication<\/strong> for the novel JAK inhibitor, following its previous approval for intermediate- and high-risk myelofibrosis, and represents the <strong>first approved clinical indication<\/strong> for the drug in an immuno-inflammatory disease.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>New Indication Approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Zepuping (gecacitinib) \u2013 pan-JAK inhibitor<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Severe alopecia areata in adults<\/td><\/tr><tr><td><strong>Previous Indication<\/strong><\/td><td>Intermediate- and high-risk myelofibrosis<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16 Jun 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Gecacitinib \u2013 novel pan-JAK inhibitor with potent activity against all four JAK kinase subtypes<\/li>\n\n\n\n<li><strong>Targets:<\/strong> JAK1, JAK2, JAK3, and TYK2 with balanced inhibition profile<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Effectively suppresses inflammation and excessive T-cell activation central to alopecia areata pathogenesis<\/li>\n\n\n\n<li><strong>Tissue Effects:<\/strong> Significantly increases dermal thickness, promotes hair follicle regeneration, and increases hair follicle density<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> First pan-JAK inhibitor approved in China specifically for severe alopecia areata<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-strategy\" class=\"wp-block-heading\">Clinical Development Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Approval Status<\/th><th>Therapeutic Area<\/th><\/tr><\/thead><tbody><tr><td><strong>Intermediate\/High-Risk Myelofibrosis<\/strong><\/td><td>Previously approved<\/td><td>Hematologic malignancies<\/td><\/tr><tr><td><strong>Severe Alopecia Areata<\/strong><\/td><td>Newly approved<\/td><td>Immuno-inflammatory diseases<\/td><\/tr><tr><td><strong>Additional Indications Under Investigation<\/strong><\/td><td>Various stages<\/td><td>Autoimmune and inflammatory conditions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The dual approval across oncology and immuno-inflammatory indications demonstrates gecacitinib&#8217;s versatility as a therapeutic agent and Zelgen&#8217;s strategic expansion beyond hematologic malignancies into autoimmune disorders.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alopecia Areata Market Opportunity:<\/strong> Global alopecia areata therapeutics market projected to reach <strong>USD 4.8 billion by 2028<\/strong>, driven by high unmet need in severe cases<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Limited treatment options for severe alopecia areata; existing JAK inhibitors include baricitinib and ritlecitinib, but gecacitinib&#8217;s pan-JAK profile offers differentiated mechanism<\/li>\n\n\n\n<li><strong>Therapeutic Gap:<\/strong> Current treatments primarily focus on immunosuppression; gecacitinib&#8217;s additional effects on dermal thickness and hair follicle regeneration address tissue repair aspects<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Analysts estimate peak annual sales of USD 600\u2013900 million globally across both indications by 2030, with China representing significant market share<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Zelgen&#8217;s successful expansion into immuno-inflammatory diseases positions the company to leverage its JAK inhibitor expertise across multiple therapeutic areas, creating a diversified revenue stream beyond its initial oncology focus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and commercial expectations for Zepuping (gecacitinib). Actual results may differ due to risks including market adoption, competitive dynamics, reimbursement decisions, and execution of Zelgen&#8217;s commercial strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688266_20260616_2VGZ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20260616_2VGZ.\"><\/object><a id=\"wp-block-file--media-afe5b735-b2d1-4d04-a0b3-bd99a96233da\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688266_20260616_2VGZ.pdf\">688266_20260616_2VGZ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688266_20260616_2VGZ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-afe5b735-b2d1-4d04-a0b3-bd99a96233da\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,15,905,246],"class_list":["post-68343","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-product-approvals","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has granted approval for its independently developed Zepuping (gecacitinib) for the treatment of severe alopecia areata in adults. This marks the second approved indication for the novel JAK inhibitor, following its previous approval for intermediate- and high-risk myelofibrosis, and represents the first approved clinical indication for the drug in an immuno-inflammatory disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68343\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has granted approval for its independently developed Zepuping (gecacitinib) for the treatment of severe alopecia areata in adults. This marks the second approved indication for the novel JAK inhibitor, following its previous approval for intermediate- and high-risk myelofibrosis, and represents the first approved clinical indication for the drug in an immuno-inflammatory disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68343\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T14:50:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T14:50:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68343#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68343\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor\",\"datePublished\":\"2026-06-16T14:50:21+00:00\",\"dateModified\":\"2026-06-16T14:50:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68343\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Product approvals\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68343#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68343\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68343\",\"name\":\"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-16T14:50:21+00:00\",\"dateModified\":\"2026-06-16T14:50:22+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has granted approval for its independently developed Zepuping (gecacitinib) for the treatment of severe alopecia areata in adults. This marks the second approved indication for the novel JAK inhibitor, following its previous approval for intermediate- and high-risk myelofibrosis, and represents the first approved clinical indication for the drug in an immuno-inflammatory disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68343#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68343\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68343#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has granted approval for its independently developed Zepuping (gecacitinib) for the treatment of severe alopecia areata in adults. This marks the second approved indication for the novel JAK inhibitor, following its previous approval for intermediate- and high-risk myelofibrosis, and represents the first approved clinical indication for the drug in an immuno-inflammatory disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68343","og_locale":"en_US","og_type":"article","og_title":"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has granted approval for its independently developed Zepuping (gecacitinib) for the treatment of severe alopecia areata in adults. This marks the second approved indication for the novel JAK inhibitor, following its previous approval for intermediate- and high-risk myelofibrosis, and represents the first approved clinical indication for the drug in an immuno-inflammatory disease.","og_url":"https:\/\/flcube.com\/?p=68343","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-16T14:50:21+00:00","article_modified_time":"2026-06-16T14:50:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68343#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68343"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor","datePublished":"2026-06-16T14:50:21+00:00","dateModified":"2026-06-16T14:50:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68343"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Product approvals","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68343#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68343","url":"https:\/\/flcube.com\/?p=68343","name":"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-16T14:50:21+00:00","dateModified":"2026-06-16T14:50:22+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has granted approval for its independently developed Zepuping (gecacitinib) for the treatment of severe alopecia areata in adults. This marks the second approved indication for the novel JAK inhibitor, following its previous approval for intermediate- and high-risk myelofibrosis, and represents the first approved clinical indication for the drug in an immuno-inflammatory disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68343#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68343"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68343#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata \u2013 First Immuno-Inflammatory Indication for Pan-JAK Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68343"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68343\/revisions"}],"predecessor-version":[{"id":68345,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68343\/revisions\/68345"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}